Evaluation of the effect of the PIR-12 compound on anxiety and locomotor activity in experimental global cerebral ischemia in rats

Abstract

A study was carried out to assess the effect of a new pyrimidine derivative (PIR-12 50 mg/kg) on anxiety and locomotor activity under conditions of global cerebral ischemia in rats. It was confirmed that the investigated compound PIR-12 helps to reduce the degree of anxiety, which is manifested in an increase in the indicators "Time at the central site" and "Time in the open arms of the maze" in 3,2 (p<0,05) and 3,1% (p<0,05). "Time in the closed arms of the labyrinth" and "the number of grooming acts" decreased against the background of the introduction of PIR-12 by 28,9% (p<0,05) and 4,1 times (p<0,05) compared with the control group animals, which surpasses the effect of the reference drug Cavinton. In addition, PIR-12 promotes an increase in the motor activity of ischemic rats: the number of hanging and standing rats was 7,4 times higher (p<0,05), 4,2 times (p<0,05), relative to the NC rat group, and the effect is comparable to the group of animals that received Cavinton.